The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion
Status:
Completed
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
Background Nicorandil is recommended as a second-line treatment for stable angina, but
randomized-controlled trials (RCTs) to evaluate the benefit of nicorandil for patients with
chronic total occlusion (CTO) are still lack.
Objective To determine whether nicorandil can improve left ventricular myocardial strain in
patients with CTO.
Methods Patients with CTO were included and were randomized to the nicorandil group and the
control group. Nicorandil was given orally 15 mg/day for 3 months in the nicorandil group.
3-dimentional-speckle tracking echocardiography (3D-STE) and the Seattle angina questionnaire
(SAQ) survey were performed at baseline and at 3 months. Participants were randomized
according to an IBM SPSS23.0-generated randomization schedule, with a 1:1 allocation to the
nicorandil group or the control group.